Aura Biosciences said today that it enrolled and dosed the 1st patient in the Phase Ib trial of its light-activated AU-011 viral nanoparticle conjugate therapy for the treatment of ocular melanoma. The company also said that the FDA granted fast track designation to its targeted treatment, which will give priority review for the company’s New Drug Application.
Administered through the eye, the company’s AU-011 therapy is composed of viral nanoparticle conjugates that selectively bind to cancer cells in the eye. The treatment is activated using an ophthalmic laser, at which point it specifically destroys tumor cells’ membranes while avoiding healthy eye structures, Aura reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Aura Biosciences wins fast track designation for light-activated nanoparticle therapy appeared first on MassDevice.